Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secretome Injection for Melasma
NCT06516419Recruiting
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Randomised, single-blind trial of AT-MSC secretome in melasma (3 arms). Primary endpoints: modified Melasma Severity Index at 84 days, Patient's Tolerability Assesment at 84 days and 5 more. Started Feb 2024; status: recruiting.
02
Drugs
AT-MSC secretome
03
Conditions
melasma
Beyond the preview
Go deeper on NCT06516419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516419.